Letter to patients suffering from Huntington’s disease
Letter to patients NP03 | 2009-12-11 | Read the full article
NP03 in development for the treatment of Huntington’s disease
On 5th November 2009, Medesis Pharma received a positive opinion from the Committee for Orphan Medicinal Products (COMP) for an orphan drug designation for the following product:
Lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington’s disease......
Read the full article
